{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:11:41Z","timestamp":1780791101800,"version":"3.54.1"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005296","name":"Universit\u00e4tsklinikum Regensburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005296","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    Proprotein convertase subtilisin\/kexin type 9 (PCSK9) is a key regulator of serum cholesterol. Its expression is particularly abundant in hepatocytes, yet its role in autoimmune liver diseases remains unclear. Here we investigated serum PCSK9 levels in patients with autoimmune liver diseases and compared them to healthy controls, with attention to sex-specific differences. Serum PCSK9 levels were measured in 100 patients with autoimmune liver diseases \u2014 57 with primary sclerosing cholangitis (PSC), 33 with primary biliary cholangitis (PBC), and 10 with autoimmune hepatitis (AIH)\u2014and 88 healthy controls. Subgroup analyses were conducted based on sex and disease type. Diagnostic performance was evaluated using receiver operating characteristic (ROC) curves. PCSK9 levels were significantly elevated in patients with autoimmune liver diseases compared to healthy controls (\n                    <jats:italic>p<\/jats:italic>\n                    \u2009&lt;\u20090.001). In male patients, serum PCSK9 levels discriminated between patients with PSC and controls. In female patients, they discriminated between patients with PBC and controls. The area under the ROC curve (AUROC) for distinguishing between these groups was 0.765\u2009\u00b1\u20090.057 and 0.834\u2009\u00b1\u20090.047, respectively. Patients with almost normal aminotransferase and cholestasis marker levels (\n                    <jats:italic>n<\/jats:italic>\n                    \u2009=\u200947) had significantly higher PCSK9 levels than controls. The AUROC was 0.788\u2009\u00b1\u20090.039 and a serum PCSK9 level of 224 ng\/ml had a sensitivity of 92% and a specificity of 60% for diagnosing autoimmune liver disease. Serum PCSK9 levels did mostly not correlate with serum cholesterol, markers of liver disease severity, the model for end stage liver disease score, or fibrosis stage. Patients who experienced decompensation or required a liver transplant during the course of their disease had PCSK9 levels similar to those who did not experience these adverse events. Serum PCSK9 levels are elevated in both male and female patients with autoimmune liver diseases, independent of cholesterol levels or fibrosis stage. PCSK9 may serve as a biomarker in the diagnosis of autoimmune liver disease, even in patients with almost normal liver function test results.\n                  <\/jats:p>","DOI":"10.1038\/s41598-025-28881-y","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:20:29Z","timestamp":1763716829000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Systemic PCSK9 elevation characterises autoimmune liver disease across sexes"],"prefix":"10.1038","volume":"15","author":[{"given":"Patricia","family":"Mester","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vlad","family":"Pavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petra","family":"Stoeckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hauke Christian","family":"Tews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Buechler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"28881_CR1","doi-asserted-by":"publisher","unstructured":"Grewal, T. & Buechler, C. Emerging insights on the diverse roles of proprotein convertase Subtilisin\/Kexin type 9 (PCSK9) in chronic liver diseases: cholesterol metabolism and beyond. Int. J. Mol. Sci. 23, 7456.  https:\/\/doi.org\/10.3390\/ijms23031070 (2022).","DOI":"10.3390\/ijms23031070"},{"key":"28881_CR2","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1093\/ehjcvp\/pvz022","volume":"5","author":"AA Momtazi-Borojeni","year":"2019","unstructured":"Momtazi-Borojeni, A. A. et al. PCSK9 and inflammation: a review of experimental and clinical evidence. Eur. Heart J. Cardiovasc. Pharmacother. 5, 237\u2013245. https:\/\/doi.org\/10.1093\/ehjcvp\/pvz022 (2019).","journal-title":"Eur. Heart J. Cardiovasc. Pharmacother"},{"key":"28881_CR3","doi-asserted-by":"publisher","first-page":"593","DOI":"10.3390\/idr16040045","volume":"16","author":"P Mester","year":"2024","unstructured":"Mester, P. et al. Proprotein convertase Subtilisin\/Kexin type 9 induction in COVID-19 is poorly associated with disease severity and cholesterol levels. Infect. Dis. Rep. 16, 593\u2013607. https:\/\/doi.org\/10.3390\/idr16040045 (2024).","journal-title":"Infect. Dis. Rep."},{"key":"28881_CR4","doi-asserted-by":"publisher","unstructured":"Barker, G. et al. Lipid and lipoprotein dysregulation in sepsis: clinical and mechanistic insights into chronic critical illness. J. Clin. Med. 10, 7456. https:\/\/doi.org\/10.3390\/jcm10081693 (2021).","DOI":"10.3390\/jcm10081693"},{"key":"28881_CR5","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.atherosclerosis.2019.07.015","volume":"288","author":"M Ruscica","year":"2019","unstructured":"Ruscica, M., Tokgozoglu, L., Corsini, A. & Sirtori, C. R. PCSK9 Inhibition and inflammation: a narrative review. Atherosclerosis 288, 146\u2013155. https:\/\/doi.org\/10.1016\/j.atherosclerosis.2019.07.015 (2019).","journal-title":"Atherosclerosis"},{"key":"28881_CR6","doi-asserted-by":"publisher","unstructured":"Grimm, J. et al. Rapid decline of serum proprotein convertase Subtilisin\/Kexin 9 (PCSK9) in Non-Cirrhotic patients with chronic hepatitis C infection receiving Direct-Acting antiviral therapy. J. Clin. Med. 10, 253.  https:\/\/doi.org\/10.3390\/jcm10081621 (2021).","DOI":"10.3390\/jcm10081621"},{"key":"28881_CR7","doi-asserted-by":"publisher","first-page":"541","DOI":"10.3233\/CH-211193","volume":"79","author":"G Peschel","year":"2021","unstructured":"Peschel, G. et al. Liver stiffness assessed by shear-wave elastography declines in parallel with immunoregulatory proteins in patients with chronic HCV infection during DAA therapy. Clin. Hemorheol. Microcircul. 79, 541\u2013555. https:\/\/doi.org\/10.3233\/CH-211193 (2021).","journal-title":"Clin. Hemorheol. Microcircul."},{"key":"28881_CR8","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1111\/jcmm.13273","volume":"21","author":"M Pirro","year":"2017","unstructured":"Pirro, M. et al. Hepatitis C virus and proprotein convertase subtilisin\/kexin type 9: a detrimental interaction to increase viral infectivity and disrupt lipid metabolism. J. Cell. Mol. Med. 21, 3150\u20133161. https:\/\/doi.org\/10.1111\/jcmm.13273 (2017).","journal-title":"J. Cell. Mol. Med."},{"key":"28881_CR9","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1161\/CIRCRESAHA.118.311227","volume":"122","author":"MD Shapiro","year":"2018","unstructured":"Shapiro, M. D., Tavori, H. & Fazio, S. PCSK9: from basic science discoveries to clinical trials. Circ. Res. 122, 1420\u20131438. https:\/\/doi.org\/10.1161\/CIRCRESAHA.118.311227 (2018).","journal-title":"Circ. Res."},{"key":"28881_CR10","doi-asserted-by":"publisher","first-page":"3654","DOI":"10.2174\/1381612824666181010123127","volume":"24","author":"E Theocharidou","year":"2018","unstructured":"Theocharidou, E. et al. The role of PCSK9 in the pathogenesis of Non-alcoholic fatty liver disease and the effect of PCSK9 inhibitors. Curr. Pharm. Des. 24, 3654\u20133657. https:\/\/doi.org\/10.2174\/1381612824666181010123127 (2018).","journal-title":"Curr. Pharm. Des."},{"key":"28881_CR11","doi-asserted-by":"publisher","first-page":"100479","DOI":"10.1016\/j.jhepr.2022.100479","volume":"4","author":"B Paul","year":"2022","unstructured":"Paul, B., Lewinska, M. & Andersen, J. B. Lipid alterations in chronic liver disease and liver cancer. JHEP Rep. 4, 100479. https:\/\/doi.org\/10.1016\/j.jhepr.2022.100479 (2022).","journal-title":"JHEP Rep."},{"key":"28881_CR12","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1590\/S0004-28032015000300011","volume":"52","author":"L Bassani","year":"2015","unstructured":"Bassani, L. et al. Lipid profile of cirrhotic patients and its association with prognostic scores: a cross-sectional study. Arq. Gastroenterol. 52, 210\u2013215. https:\/\/doi.org\/10.1590\/S0004-28032015000300011 (2015).","journal-title":"Arq. Gastroenterol."},{"key":"28881_CR13","doi-asserted-by":"publisher","first-page":"155505","DOI":"10.1016\/j.phymed.2024.155505","volume":"128","author":"L Han","year":"2024","unstructured":"Han, L. et al. A promising therapy for fatty liver disease: PCSK9 inhibitors. Phytomedicine 128, 155505. https:\/\/doi.org\/10.1016\/j.phymed.2024.155505 (2024).","journal-title":"Phytomedicine"},{"key":"28881_CR14","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1007\/s00508-019-01544-5","volume":"131","author":"LW Unger","year":"2019","unstructured":"Unger, L. W. et al. Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. Wien Klin. Wochenschr. 131, 395\u2013403. https:\/\/doi.org\/10.1007\/s00508-019-01544-5 (2019).","journal-title":"Wien Klin. Wochenschr"},{"key":"28881_CR15","doi-asserted-by":"publisher","unstructured":"Buechler, C. & Aslanidis, C. Role of lipids in pathophysiology, diagnosis and therapy of hepatocellular carcinoma. Biochim. Biophys. Acta Mol. Cell. Biol. Lipids. 1865, 253. https:\/\/doi.org\/10.1016\/j.bbalip.2020.158658 (2020).","DOI":"10.1016\/j.bbalip.2020.158658"},{"key":"28881_CR16","doi-asserted-by":"publisher","first-page":"17167","DOI":"10.1038\/s41598-019-53603-6","volume":"9","author":"JS Lee","year":"2019","unstructured":"Lee, J. S. et al. PCSK9 Inhibition as a novel therapeutic target for alcoholic liver disease. Sci. Rep. 9, 17167. https:\/\/doi.org\/10.1038\/s41598-019-53603-6 (2019).","journal-title":"Sci. Rep."},{"key":"28881_CR17","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.jhepr.2019.10.009","volume":"1","author":"PF Lebeau","year":"2019","unstructured":"Lebeau, P. F. et al. Pcsk9 knockout exacerbates diet-induced non-alcoholic steatohepatitis, fibrosis and liver injury in mice. JHEP Rep. 1, 418\u2013429. https:\/\/doi.org\/10.1016\/j.jhepr.2019.10.009 (2019).","journal-title":"JHEP Rep."},{"key":"28881_CR18","doi-asserted-by":"publisher","first-page":"113621","DOI":"10.1016\/j.intimp.2024.113621","volume":"143","author":"T Mijiti","year":"2024","unstructured":"Mijiti, T. et al. Inhibition of hepatic PCSK9 as a novel therapeutic target ameliorates metabolic steatohepatitis in mice. Int. Immunopharmacol. 143, 113621. https:\/\/doi.org\/10.1016\/j.intimp.2024.113621 (2024).","journal-title":"Int. Immunopharmacol."},{"key":"28881_CR19","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1001\/jamacardio.2020.5341","volume":"6","author":"A Rimbert","year":"2021","unstructured":"Rimbert, A., Smati, S., Dijk, W., Le May, C. & Cariou, B. Genetic Inhibition of PCSK9 and liver function. JAMA Cardiol. 6, 353\u2013354. https:\/\/doi.org\/10.1001\/jamacardio.2020.5341 (2021).","journal-title":"JAMA Cardiol."},{"key":"28881_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.4254\/wjh.v12.i12.1258","volume":"12","author":"M Shafiq","year":"2020","unstructured":"Shafiq, M., Walmann, T., Nutalapati, V., Gibson, C. & Zafar, Y. Effects of proprotein convertase subtilisin\/kexin type-9 inhibitors on fatty liver. World J. Hepatol. 12, 1258\u20131266. https:\/\/doi.org\/10.4254\/wjh.v12.i12.1258 (2020).","journal-title":"World J. Hepatol."},{"key":"28881_CR21","doi-asserted-by":"publisher","first-page":"3187","DOI":"10.1007\/s11845-023-03323-8","volume":"192","author":"Y Meng","year":"2023","unstructured":"Meng, Y., Zheng, X., Zhang, Z., Geng, H. & Li, X. Circulating PCSK9 relates to aggravated disease activity, Th17\/Treg imbalance, and predicts treatment outcome of conventional synthetic DMARDs in rheumatoid arthritis patients. Ir. J. Med. Sci. 192, 3187\u20133194. https:\/\/doi.org\/10.1007\/s11845-023-03323-8 (2023).","journal-title":"Ir. J. Med. Sci."},{"key":"28881_CR22","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1186\/s13075-023-03122-7","volume":"25","author":"W Xie","year":"2023","unstructured":"Xie, W., Li, J., Du, H. & Xia, J. Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study. Arthritis Res. Ther. 25, 148. https:\/\/doi.org\/10.1186\/s13075-023-03122-7 (2023).","journal-title":"Arthritis Res. Ther."},{"key":"28881_CR23","doi-asserted-by":"publisher","first-page":"1160312","DOI":"10.3389\/fimmu.2023.1160312","volume":"14","author":"H Tao","year":"2023","unstructured":"Tao, H. et al. Lipids, lipid-lowering agents, and inflammatory bowel disease: a Mendelian randomization study. Front. Immunol. 14, 1160312. https:\/\/doi.org\/10.3389\/fimmu.2023.1160312 (2023).","journal-title":"Front. Immunol."},{"key":"28881_CR24","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1097\/MCG.0000000000001607","volume":"56","author":"C Marinelli","year":"2022","unstructured":"Marinelli, C. et al. Serum levels of PCSK9 are increased in patients with active ulcerative colitis representing a potential biomarker of disease activity: a Cross-sectional study. J. Clin. Gastroenterol. 56, 787\u2013793. https:\/\/doi.org\/10.1097\/MCG.0000000000001607 (2022).","journal-title":"J. Clin. Gastroenterol."},{"key":"28881_CR25","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1007\/s11845-023-03440-4","volume":"193","author":"J Deng","year":"2024","unstructured":"Deng, J. et al. Longitudinal variation of serum PCSK9 in ulcerative colitis: association with disease activity, T helper 1\/2\/17 cells, and clinical response of tumor necrosis factor inhibitor. Ir. J. Med. Sci. 193, 165\u2013172. https:\/\/doi.org\/10.1007\/s11845-023-03440-4 (2024).","journal-title":"Ir. J. Med. Sci."},{"key":"28881_CR26","doi-asserted-by":"crossref","unstructured":"Hettenbach, A. et al. Cholesteryl ester species but not serum proprotein convertase subtilisin\/kexin type 9 levels decline in male patients with active inflammatory bowel disease. Pathophysiol. Press. (2025).","DOI":"10.3390\/pathophysiology32020013"},{"key":"28881_CR27","doi-asserted-by":"publisher","unstructured":"Zhao, J. et al. Lipid-lowering drugs and inflammatory bowel disease\u2019s risk: a drug-target Mendelian randomization study. Diabetol. Metab. Syndr. 16, 36.  https:\/\/doi.org\/10.1186\/s13098-023-01252-1 (2024).","DOI":"10.1186\/s13098-023-01252-1"},{"key":"28881_CR28","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1038\/s12276-023-01042-9","volume":"55","author":"YS Kim","year":"2023","unstructured":"Kim, Y. S., Hurley, E. H., Park, Y. & Ko, S. Primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD): a condition exemplifying the crosstalk of the gut-liver axis. Exp. Mol. Med. 55, 1380\u20131387. https:\/\/doi.org\/10.1038\/s12276-023-01042-9 (2023).","journal-title":"Exp. Mol. Med."},{"key":"28881_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2023.09.031","author":"KN van Munster","year":"2023","unstructured":"van Munster, K. N., Bergquist, A. & Ponsioen, C. Y. Inflammatory bowel disease and primary sclerosing cholangitis: one disease or two? J. Hepatol. https:\/\/doi.org\/10.1016\/j.jhep.2023.09.031 (2023).","journal-title":"J. Hepatol."},{"key":"28881_CR30","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.dld.2011.07.020","volume":"44","author":"E Sinakos","year":"2012","unstructured":"Sinakos, E., Abbas, G., Jorgensen, R. A. & Lindor, K. D. Serum lipids in primary sclerosing cholangitis. Dig. Liver Dis. 44, 44\u201348. https:\/\/doi.org\/10.1016\/j.dld.2011.07.020 (2012).","journal-title":"Dig. Liver Dis."},{"key":"28881_CR31","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1007\/s40265-021-01545-7","volume":"81","author":"S Hasegawa","year":"2021","unstructured":"Hasegawa, S. et al. Cholestatic liver disease: current treatment strategies and new therapeutic agents. Drugs 81, 1181\u20131192. https:\/\/doi.org\/10.1007\/s40265-021-01545-7 (2021).","journal-title":"Drugs"},{"key":"28881_CR32","doi-asserted-by":"publisher","first-page":"106621","DOI":"10.1016\/j.jsbmb.2024.106621","volume":"245","author":"S Matysik","year":"2025","unstructured":"Matysik, S. et al. Unique sterol metabolite shifts in inflammatory bowel disease and primary sclerosing cholangitis. J. Steroid Biochem. Mol. Biol. 245, 106621. https:\/\/doi.org\/10.1016\/j.jsbmb.2024.106621 (2025).","journal-title":"J. Steroid Biochem. Mol. Biol."},{"key":"28881_CR33","doi-asserted-by":"publisher","unstructured":"Rabiee, A. & Silveira, M. G. Primary sclerosing cholangitis. Transl. Gastroenterol. Hepatol. 6, 362.  https:\/\/doi.org\/10.21037\/tgh-20-266 (2021).","DOI":"10.21037\/tgh-20-266"},{"key":"28881_CR34","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1053\/j.gastro.2024.01.049","volume":"166","author":"PJ Trivedi","year":"2024","unstructured":"Trivedi, P. J., Hirschfield, G. M., Adams, D. H. & Vierling, J. M. Immunopathogenesis of primary biliary cholangitis, primary sclerosing cholangitis and autoimmune hepatitis: themes and concepts. Gastroenterology 166, 995\u20131019. https:\/\/doi.org\/10.1053\/j.gastro.2024.01.049 (2024).","journal-title":"Gastroenterology"},{"key":"28881_CR35","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1016\/j.autrev.2014.01.041","volume":"13","author":"CL Bowlus","year":"2014","unstructured":"Bowlus, C. L. & Gershwin, M. E. The diagnosis of primary biliary cirrhosis. Autoimmun. Rev. 13, 441\u2013444. https:\/\/doi.org\/10.1016\/j.autrev.2014.01.041 (2014).","journal-title":"Autoimmun. Rev."},{"key":"28881_CR36","doi-asserted-by":"publisher","first-page":"867","DOI":"10.3238\/arztebl.2013.0867","volume":"110","author":"H Lutz","year":"2013","unstructured":"Lutz, H., Trautwein, C. & Tischendorf, J. W. Primary sclerosing cholangitis: diagnosis and treatment. Dtsch. Arztebl Int. 110, 867\u2013874. https:\/\/doi.org\/10.3238\/arztebl.2013.0867 (2013).","journal-title":"Dtsch. Arztebl Int."},{"key":"28881_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1136\/flgastro-2018-101124","volume":"10","author":"MI Wah-Suarez","year":"2019","unstructured":"Wah-Suarez, M. I., Danford, C. J., Patwardhan, V. R., Jiang, Z. G. & Bonder, A. Hyperlipidaemia in primary biliary cholangitis: treatment, safety and efficacy. Frontline Gastroenterol. 10, 401\u2013408. https:\/\/doi.org\/10.1136\/flgastro-2018-101124 (2019).","journal-title":"Frontline Gastroenterol."},{"key":"28881_CR38","doi-asserted-by":"publisher","first-page":"266","DOI":"10.14218\/JCTH.2014.00024","volume":"2","author":"RM Marchioni Beery","year":"2014","unstructured":"Marchioni Beery, R. M., Vaziri, H. & Forouhar, F. Primary biliary cirrhosis and primary sclerosing cholangitis: a review featuring a women\u2019s health perspective. J. Clin. Transl Hepatol. 2, 266\u2013284. https:\/\/doi.org\/10.14218\/JCTH.2014.00024 (2014).","journal-title":"J. Clin. Transl Hepatol."},{"key":"28881_CR39","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/apt.12563","volume":"39","author":"J Chen","year":"2014","unstructured":"Chen, J., Eslick, G. D. & Weltman, M. Systematic review with meta-analysis: clinical manifestations and management of autoimmune hepatitis in the elderly. Aliment. Pharmacol. Ther. 39, 117\u2013124. https:\/\/doi.org\/10.1111\/apt.12563 (2014).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"28881_CR40","doi-asserted-by":"publisher","unstructured":"Chaudhary, A. & Kumar, V. Rare diseases: a comprehensive literature review and future directions. J. Rare Dis. 4, 253.  https:\/\/doi.org\/10.1007\/s44162-025-00099-6 (2025).","DOI":"10.1007\/s44162-025-00099-6"},{"key":"28881_CR41","doi-asserted-by":"publisher","unstructured":"European Association for the Study of the, L. EASL clinical practice guidelines on the management of autoimmune hepatitis. J. Hepatol. 83, 453\u2013501. https:\/\/doi.org\/10.1016\/j.jhep.2025.03.017 (2025).","DOI":"10.1016\/j.jhep.2025.03.017"},{"key":"28881_CR42","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.jhep.2017.03.022","volume":"67","author":"European Association for the Study of the, L. EASL Clinical Practice Guidelines","year":"2017","unstructured":"European Association for the Study of the, L. EASL Clinical Practice Guidelines. The diagnosis and management of patients with primary biliary cholangitis. J. Hepatol. 67, 145\u2013172. https:\/\/doi.org\/10.1016\/j.jhep.2017.03.022 (2017).","journal-title":"J. Hepatol."},{"key":"28881_CR43","doi-asserted-by":"publisher","unstructured":"European Association for the Study of. the, L. EASL clinical practice guidelines on sclerosing cholangitis. J. Hepatol. 77, 761\u2013806. https:\/\/doi.org\/10.1016\/j.jhep.2022.05.011 (2022).","DOI":"10.1016\/j.jhep.2022.05.011"},{"key":"28881_CR44","doi-asserted-by":"publisher","first-page":"23","DOI":"10.5604\/01.3001.0012.7858","volume":"18","author":"RS Goertz","year":"2019","unstructured":"Goertz, R. S. et al. Acoustic radiation force impulse (ARFI) elastography in autoimmune and cholestatic liver diseases. Ann. Hepatol. 18, 23\u201329. https:\/\/doi.org\/10.5604\/01.3001.0012.7858 (2019).","journal-title":"Ann. Hepatol."},{"key":"28881_CR45","doi-asserted-by":"publisher","unstructured":"Sporea, I. et al. The usefulnes of acoustic radiation force impulse (ARFI) elastography (ARFI) for evaluation of liver fibrosis \u2013 large monocentric experience. Ultraschall Med. 34, 253.  https:\/\/doi.org\/10.1055\/s-0033-1354805 (2013).","DOI":"10.1055\/s-0033-1354805"},{"key":"28881_CR46","doi-asserted-by":"publisher","unstructured":"Rennebaum, F. et al. Elevated liver fibrosis progression in isolated PSC patients and increased malignancy risk in a PSC-IBD cohort: a retrospective study. Int. J. Mol. Sci. 24, 2563.  https:\/\/doi.org\/10.3390\/ijms242015431 (2023).","DOI":"10.3390\/ijms242015431"},{"key":"28881_CR47","first-page":"2223","volume":"59","author":"DE Johnston","year":"1999","unstructured":"Johnston, D. E. Special considerations in interpreting liver function tests. Am. Fam Physician. 59, 2223\u20132230 (1999).","journal-title":"Am. Fam Physician"},{"key":"28881_CR48","doi-asserted-by":"publisher","first-page":"1688","DOI":"10.4254\/wjh.v13.i11.1688","volume":"13","author":"MA Kalas","year":"2021","unstructured":"Kalas, M. A., Chavez, L., Leon, M., Taweesedt, P. T. & Surani, S. Abnormal liver enzymes: a review for clinicians. World J. Hepatol. 13, 1688\u20131698. https:\/\/doi.org\/10.4254\/wjh.v13.i11.1688 (2021).","journal-title":"World J. Hepatol."},{"key":"28881_CR49","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.jcmgh.2023.09.001","volume":"17","author":"DB Rosoff","year":"2024","unstructured":"Rosoff, D. B. et al. Assessing the impact of PCSK9 and HMGCR Inhibition on liver function: Drug-Target Mendelian randomization analyses in four ancestries. Cell. Mol. Gastroenterol. Hepatol. 17, 29\u201340. https:\/\/doi.org\/10.1016\/j.jcmgh.2023.09.001 (2024).","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"28881_CR50","doi-asserted-by":"publisher","first-page":"S97","DOI":"10.1016\/j.atherosclerosis.2023.06.353","volume":"379","author":"P Blanke","year":"2023","unstructured":"Blanke, P. et al. Prevalence of dyslipidaemia in Germany. Atherosclerosis 379, S97\u2013S97 (2023).","journal-title":"Atherosclerosis"},{"key":"28881_CR51","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1038\/s41392-023-01690-3","volume":"9","author":"X Bao","year":"2024","unstructured":"Bao, X. et al. Targeting proprotein convertase subtilisin\/kexin type 9 (PCSK9): from bench to bedside. Signal. Transduct. Target. Ther. 9, 13. https:\/\/doi.org\/10.1038\/s41392-023-01690-3 (2024).","journal-title":"Signal. Transduct. Target. Ther."},{"key":"28881_CR52","doi-asserted-by":"publisher","unstructured":"Reshetnyak, V. I. & Maev, I. V. Features of lipid metabolism disorders in primary biliary cholangitis. Biomedicines 10, 1452. https:\/\/doi.org\/10.3390\/biomedicines10123046 (2022).","DOI":"10.3390\/biomedicines10123046"},{"key":"28881_CR53","doi-asserted-by":"publisher","unstructured":"Grundy, S. M. 2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines. . Circulation 139, e1082-e1143. https:\/\/doi.org\/10.1161\/CIR.0000000000000625 (2019).","DOI":"10.1161\/CIR.0000000000000625"},{"key":"28881_CR54","doi-asserted-by":"publisher","first-page":"117954761773137","DOI":"10.1177\/1179547617731375","volume":"10","author":"S Bergland Ellingsen","year":"2017","unstructured":"Bergland Ellingsen, S., Nordmo, E. & Lappegard, K. T. Recurrence and severe worsening of hepatotoxicity after reintroduction of Atorvastatin in combination with Ezetimibe. Clin. Med. Insights Case Rep. 10, 1179547617731375. https:\/\/doi.org\/10.1177\/1179547617731375 (2017).","journal-title":"Clin. Med. Insights Case Rep."},{"key":"28881_CR55","doi-asserted-by":"publisher","first-page":"e82315","DOI":"10.7759\/cureus.82315","volume":"17","author":"J Loeza-Suarez","year":"2025","unstructured":"Loeza-Suarez, J., Garcia-Luna, D. C., Hernandez-Miron, J., Ramirez-Marcial, R. & Valero-Gaona, G. A. Autoimmune hepatitis (AIH) related to Drug-Induced liver injury (DILI) due to Atorvastatin. Cureus 17, e82315. https:\/\/doi.org\/10.7759\/cureus.82315 (2025).","journal-title":"Cureus"},{"key":"28881_CR56","doi-asserted-by":"publisher","first-page":"380","DOI":"10.31083\/j.rcm2311380","volume":"23","author":"Y Xiao","year":"2022","unstructured":"Xiao, Y. et al. PCSK9 inhibitor: safe alternative to fill the treatment gap in Statin-Limited conditions? Rev. Cardiovasc. Med. 23, 380. https:\/\/doi.org\/10.31083\/j.rcm2311380 (2022).","journal-title":"Rev. Cardiovasc. Med."},{"key":"28881_CR57","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1007\/s00535-020-01681-z","volume":"55","author":"M Vesterhus","year":"2020","unstructured":"Vesterhus, M. & Karlsen, T. H. Emerging therapies in primary sclerosing cholangitis: pathophysiological basis and clinical opportunities. J. Gastroenterol. 55, 588\u2013614. https:\/\/doi.org\/10.1007\/s00535-020-01681-z (2020).","journal-title":"J. Gastroenterol."},{"key":"28881_CR58","doi-asserted-by":"publisher","unstructured":"Cylwik, B. et al. The diagnostic value of fibrotest and hepascore as Non-Invasive markers of liver fibrosis in primary sclerosing cholangitis (PSC). J. Clin. Med. 12, 2563. https:\/\/doi.org\/10.3390\/jcm12247552 (2023).","DOI":"10.3390\/jcm12247552"},{"key":"28881_CR59","doi-asserted-by":"publisher","first-page":"688","DOI":"10.4065\/75.7.688","volume":"75","author":"WR Kim","year":"2000","unstructured":"Kim, W. R. et al. A revised natural history model for primary sclerosing cholangitis. Mayo Clin. Proc. 75, 688\u2013694. https:\/\/doi.org\/10.4065\/75.7.688 (2000).","journal-title":"Mayo Clin. Proc."},{"key":"28881_CR60","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1111\/jgh.16850","volume":"40","author":"D Jayabalan","year":"2025","unstructured":"Jayabalan, D. et al. Natural history and predictors of clinical outcomes in autoimmune liver diseases: A multicenter study. J. Gastroenterol. Hepatol. 40, 731\u2013740. https:\/\/doi.org\/10.1111\/jgh.16850 (2025).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"28881_CR61","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1111\/jgh.13333","volume":"31","author":"Y Huang","year":"2016","unstructured":"Huang, Y. et al. Serum models accurately predict liver-related clinical outcomes in chronic hepatitis C. J. Gastroenterol. Hepatol. 31, 1736\u20131741. https:\/\/doi.org\/10.1111\/jgh.13333 (2016).","journal-title":"J. Gastroenterol. Hepatol."},{"key":"28881_CR62","doi-asserted-by":"publisher","unstructured":"Schmeltzer, P. A. & Russo, M. W. Systematic review of prognostic models compared to the Mayo risk score for primary sclerosing cholangitis. J. Clin. Med. 10, 2563.  https:\/\/doi.org\/10.3390\/jcm10194476 (2021).","DOI":"10.3390\/jcm10194476"},{"key":"28881_CR63","doi-asserted-by":"publisher","unstructured":"Ruf, A., Dirchwolf, M. & Freeman, R. B. From Child-Pugh to MELD score and beyond: taking a walk down memory lane. Ann. Hepatol. 27, 100535. https:\/\/doi.org\/10.1016\/j.aohep.2021.100535 (2022).","DOI":"10.1016\/j.aohep.2021.100535"},{"key":"28881_CR64","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/s0168-8278(00)80061-6","volume":"32","author":"P Angulo","year":"2000","unstructured":"Angulo, P. et al. Serum autoantibodies in patients with primary sclerosing cholangitis. J. Hepatol. 32, 182\u2013187. https:\/\/doi.org\/10.1016\/s0168-8278(00)80061-6 (2000).","journal-title":"J. Hepatol."},{"key":"28881_CR65","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1007\/s00535-023-02006-6","volume":"58","author":"H Yoshida","year":"2023","unstructured":"Yoshida, H. et al. Anti-integrin alphavbeta6 autoantibodies in patients with primary sclerosing cholangitis. J. Gastroenterol. 58, 778\u2013789. https:\/\/doi.org\/10.1007\/s00535-023-02006-6 (2023).","journal-title":"J. Gastroenterol."},{"key":"28881_CR66","doi-asserted-by":"publisher","first-page":"110962","DOI":"10.1016\/j.intimp.2023.110962","volume":"124","author":"M Yu","year":"2023","unstructured":"Yu, M. et al. PCSK9 Inhibition ameliorates experimental autoimmune myocarditis by reducing Th17 cell differentiation through LDLR\/STAT-3\/ROR-gammat pathway. Int. Immunopharmacol. 124, 110962. https:\/\/doi.org\/10.1016\/j.intimp.2023.110962 (2023).","journal-title":"Int. Immunopharmacol."},{"key":"28881_CR67","doi-asserted-by":"publisher","first-page":"607073","DOI":"10.1155\/2013\/607073","volume":"2013","author":"M Abe","year":"2013","unstructured":"Abe, M., Hiasa, Y. & Onji, M. T helper 17 cells in autoimmune liver diseases. Clin. Dev. Immunol. 2013, 607073. https:\/\/doi.org\/10.1155\/2013\/607073 (2013).","journal-title":"Clin. Dev. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28881-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28881-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28881-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T09:20:31Z","timestamp":1763716831000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-28881-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":67,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["28881"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-28881-y","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"assertion":[{"value":"8 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"41185"}}